1008112-39-7 Usage
General Description
4-Ethynyl-2-fluorobenzenamine is a chemical compound with the molecular formula C8H6FHN. It is a yellow crystalline solid that is used in organic synthesis and research. 4-Ethynyl-2-fluorobenzenamine contains a benzene ring with an ethynyl and a fluorine group attached to it, as well as an amine functional group. It is a stable and non-reactive compound under normal conditions, and it has potential applications in the manufacturing of pharmaceuticals and other organic compounds. 4-Ethynyl-2-fluorobenzenamine is of interest to researchers and chemists due to its unique structure and potential utility in various chemical reactions and processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1008112-39-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,8,1,1 and 2 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1008112-39:
(9*1)+(8*0)+(7*0)+(6*8)+(5*1)+(4*1)+(3*2)+(2*3)+(1*9)=87
87 % 10 = 7
So 1008112-39-7 is a valid CAS Registry Number.
1008112-39-7Relevant articles and documents
LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents
Kurasaki, Haruaki,Tsuda, Kosuke,Shinoyama, Mariko,Takaya, Noriko,Yamaguchi, Yuko,Kishii, Ryuta,Iwase, Kazuhiko,Ando, Naoki,Nomura, Masahiro,Kohno, Yasushi
supporting information, p. 623 - 628 (2016/07/06)
Herein we report a scaffold-hopping approach to identify a new scaffold with a zinc binding headgroup. Structural information was used to give novel oxazolidinone-based LpxC inhibitors. In particular, the most potent compound, 23j, showed a low efflux ratio, nanomolar potencies against E. coli LpxC enzyme, and excellent antibacterial activity against E. coli and K. pneumoniae. Computational docking was used to predict the interaction between 23j and E. coli LpxC, suggesting that the interactions with C207 and C63 contribute to the strong activity. These results provide new insights into the design of next-generation LpxC inhibitors.
